http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 20 May 2026 16:11:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++ORAGENICS+INC++++++++++++++++++++++++/26528406.html si-local-file:///var/storage/secattach/20260520/26528406.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++ORAGENICS+INC++++++++++++++++++++++++/26528406.html Wed, 20 May 2026 16:11:00 -0400 O.00978679 OGEN http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++ORAGENICS+INC++++++++++++++++++++++++/26528406.html si-local-file:///var/storage/secattach/20260520/26528406.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++ORAGENICS+INC++++++++++++++++++++++++/26528406.html Wed, 20 May 2026 16:11:00 -0400 O.00978679 OGEN http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++ORAGENICS+INC+++++++++++++For%3A+May+20/26528268.html si-local-file:///var/storage/secattach/20260520/26528268.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++ORAGENICS+INC+++++++++++++For%3A+May+20/26528268.html Wed, 20 May 2026 16:06:00 -0400 O.00978679 OGEN http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++ORAGENICS+INC+++++++++++++For%3A+May+20/26528268.html si-local-file:///var/storage/secattach/20260520/26528268.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++ORAGENICS+INC+++++++++++++For%3A+May+20/26528268.html Wed, 20 May 2026 16:06:00 -0400 O.00978679 OGEN http://www.streetinsider.com/Press+Releases/Oragenics+to+Present+at+Sidoti%E2%80%99s+Micro-Cap+Virtual+Investor+Conference+May+20-21/26518080.html <p align="justify"><strong>Sarasota, FL, May 19, 2026 (GLOBE NEWSWIRE) -- </strong>Oragenics, Inc. (NYSE American: OGEN) (&quot;Oragenics&quot; or the &quot;Company&quot;), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, will present and host one-on-one meetings with investors at Sidoti’s Micro-Cap Virtual Investor Conference, taking place on May 20-21, 2026.</p> <p align="justify">The presentation will begin at 3:15 ET on May 21, 2026 and can be accessed live here: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=n7TMtW0bYyMXz7G9deH866mpdXRzJw8GqzyNHeMJbfaZDwp-qbxHf38nSwIapDI6gQToDBXo8TD0mKQiesqybKQOgbEjcbfq7do2Gy71oX7MgXe1PnVKfD1H3s7TEBMiNAtmG6XstNQoLeS_g_cbdh_lUxNc6_SdsvXCe1CfGEMaaqWSuND7eTwu5NEcfUGNZ66cvsabvaUbx_hUL49Ysg==" rel="nofollow" target="_blank">https://sidoti.zoom.us/webinar/register/WN_4MxVYrk0Sl2JK5ByzTN6Pg</a>. Oragenics will also host virtual one-on-ones with investors on Wednesday and Thursday, May 20-21, 2026. To register for the presentation or one-on-ones, visit <a target="_blank" href="https://www.globenewswire.com/Tracker?data=yC_T3j3QY9A5tFl7LeM-_clsUj9w9Q8jBYRMAOvuDATqlE8o0nxF2hLpcu5HD1vMO8CbWqGYsSp7Kr1eICEEYuWJD_rms9JBOnWdrjPjFiE=" rel="nofollow" target="_blank">www.sidoti.com/events</a>. Registration is free and http://www.streetinsider.com/Press+Releases/Oragenics+to+Present+at+Sidoti%E2%80%99s+Micro-Cap+Virtual+Investor+Conference+May+20-21/26518080.html Tue, 19 May 2026 08:45:00 -0400 A.26105522 O.00978679 O.22245537 OGEN http://www.streetinsider.com/Press+Releases/Oragenics+to+Present+at+Sidoti%E2%80%99s+Micro-Cap+Virtual+Investor+Conference+May+20-21/26518080.html <p align="justify"><strong>Sarasota, FL, May 19, 2026 (GLOBE NEWSWIRE) -- </strong>Oragenics, Inc. (NYSE American: OGEN) (&quot;Oragenics&quot; or the &quot;Company&quot;), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, will present and host one-on-one meetings with investors at Sidoti’s Micro-Cap Virtual Investor Conference, taking place on May 20-21, 2026.</p> <p align="justify">The presentation will begin at 3:15 ET on May 21, 2026 and can be accessed live here: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=n7TMtW0bYyMXz7G9deH866mpdXRzJw8GqzyNHeMJbfaZDwp-qbxHf38nSwIapDI6gQToDBXo8TD0mKQiesqybKQOgbEjcbfq7do2Gy71oX7MgXe1PnVKfD1H3s7TEBMiNAtmG6XstNQoLeS_g_cbdh_lUxNc6_SdsvXCe1CfGEMaaqWSuND7eTwu5NEcfUGNZ66cvsabvaUbx_hUL49Ysg==" rel="nofollow" target="_blank">https://sidoti.zoom.us/webinar/register/WN_4MxVYrk0Sl2JK5ByzTN6Pg</a>. Oragenics will also host virtual one-on-ones with investors on Wednesday and Thursday, May 20-21, 2026. To register for the presentation or one-on-ones, visit <a target="_blank" href="https://www.globenewswire.com/Tracker?data=yC_T3j3QY9A5tFl7LeM-_clsUj9w9Q8jBYRMAOvuDATqlE8o0nxF2hLpcu5HD1vMO8CbWqGYsSp7Kr1eICEEYuWJD_rms9JBOnWdrjPjFiE=" rel="nofollow" target="_blank">www.sidoti.com/events</a>. Registration is free and http://www.streetinsider.com/Press+Releases/Oragenics+to+Present+at+Sidoti%E2%80%99s+Micro-Cap+Virtual+Investor+Conference+May+20-21/26518080.html Tue, 19 May 2026 08:45:00 -0400 A.26105522 O.00978679 O.22245537 OGEN http://www.streetinsider.com/Press+Releases/Oragenics+to+Present+at+Sidoti%E2%80%99s+Micro-Cap+Virtual+Investor+Conference+May+20-21/26518080.html <p align="justify"><strong>Sarasota, FL, May 19, 2026 (GLOBE NEWSWIRE) -- </strong>Oragenics, Inc. (NYSE American: OGEN) (&quot;Oragenics&quot; or the &quot;Company&quot;), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, will present and host one-on-one meetings with investors at Sidoti’s Micro-Cap Virtual Investor Conference, taking place on May 20-21, 2026.</p> <p align="justify">The presentation will begin at 3:15 ET on May 21, 2026 and can be accessed live here: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=n7TMtW0bYyMXz7G9deH866mpdXRzJw8GqzyNHeMJbfaZDwp-qbxHf38nSwIapDI6gQToDBXo8TD0mKQiesqybKQOgbEjcbfq7do2Gy71oX7MgXe1PnVKfD1H3s7TEBMiNAtmG6XstNQoLeS_g_cbdh_lUxNc6_SdsvXCe1CfGEMaaqWSuND7eTwu5NEcfUGNZ66cvsabvaUbx_hUL49Ysg==" rel="nofollow" target="_blank">https://sidoti.zoom.us/webinar/register/WN_4MxVYrk0Sl2JK5ByzTN6Pg</a>. Oragenics will also host virtual one-on-ones with investors on Wednesday and Thursday, May 20-21, 2026. To register for the presentation or one-on-ones, visit <a target="_blank" href="https://www.globenewswire.com/Tracker?data=yC_T3j3QY9A5tFl7LeM-_clsUj9w9Q8jBYRMAOvuDATqlE8o0nxF2hLpcu5HD1vMO8CbWqGYsSp7Kr1eICEEYuWJD_rms9JBOnWdrjPjFiE=" rel="nofollow" target="_blank">www.sidoti.com/events</a>. Registration is free and http://www.streetinsider.com/Press+Releases/Oragenics+to+Present+at+Sidoti%E2%80%99s+Micro-Cap+Virtual+Investor+Conference+May+20-21/26518080.html Tue, 19 May 2026 08:45:00 -0400 A.26105522 O.00978679 O.22245537 OGEN http://www.streetinsider.com/Press+Releases/Oragenics+to+Present+at+Sidoti%E2%80%99s+Micro-Cap+Virtual+Investor+Conference+May+20-21/26518080.html <p align="justify"><strong>Sarasota, FL, May 19, 2026 (GLOBE NEWSWIRE) -- </strong>Oragenics, Inc. (NYSE American: OGEN) (&quot;Oragenics&quot; or the &quot;Company&quot;), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, will present and host one-on-one meetings with investors at Sidoti’s Micro-Cap Virtual Investor Conference, taking place on May 20-21, 2026.</p> <p align="justify">The presentation will begin at 3:15 ET on May 21, 2026 and can be accessed live here: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=n7TMtW0bYyMXz7G9deH866mpdXRzJw8GqzyNHeMJbfaZDwp-qbxHf38nSwIapDI6gQToDBXo8TD0mKQiesqybKQOgbEjcbfq7do2Gy71oX7MgXe1PnVKfD1H3s7TEBMiNAtmG6XstNQoLeS_g_cbdh_lUxNc6_SdsvXCe1CfGEMaaqWSuND7eTwu5NEcfUGNZ66cvsabvaUbx_hUL49Ysg==" rel="nofollow" target="_blank">https://sidoti.zoom.us/webinar/register/WN_4MxVYrk0Sl2JK5ByzTN6Pg</a>. Oragenics will also host virtual one-on-ones with investors on Wednesday and Thursday, May 20-21, 2026. To register for the presentation or one-on-ones, visit <a target="_blank" href="https://www.globenewswire.com/Tracker?data=yC_T3j3QY9A5tFl7LeM-_clsUj9w9Q8jBYRMAOvuDATqlE8o0nxF2hLpcu5HD1vMO8CbWqGYsSp7Kr1eICEEYuWJD_rms9JBOnWdrjPjFiE=" rel="nofollow" target="_blank">www.sidoti.com/events</a>. Registration is free and http://www.streetinsider.com/Press+Releases/Oragenics+to+Present+at+Sidoti%E2%80%99s+Micro-Cap+Virtual+Investor+Conference+May+20-21/26518080.html Tue, 19 May 2026 08:45:00 -0400 A.26105522 O.00978679 O.22245537 OGEN http://www.streetinsider.com/Globe+Newswire/Oragenics+to+Present+at+Sidoti%E2%80%99s+Micro-Cap+Virtual+Investor+Conference+May+20-21/26518080.html <p align="justify"><strong>Sarasota, FL, May 19, 2026 (GLOBE NEWSWIRE) -- </strong>Oragenics, Inc. (NYSE American: OGEN) (&quot;Oragenics&quot; or the &quot;Company&quot;), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, will present and host one-on-one meetings with investors at Sidoti’s Micro-Cap Virtual Investor Conference, taking place on May 20-21, 2026.</p> <p align="justify">The presentation will begin at 3:15 ET on May 21, 2026 and can be accessed live here: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=n7TMtW0bYyMXz7G9deH866mpdXRzJw8GqzyNHeMJbfaZDwp-qbxHf38nSwIapDI6gQToDBXo8TD0mKQiesqybKQOgbEjcbfq7do2Gy71oX7MgXe1PnVKfD1H3s7TEBMiNAtmG6XstNQoLeS_g_cbdh_lUxNc6_SdsvXCe1CfGEMaaqWSuND7eTwu5NEcfUGNZ66cvsabvaUbx_hUL49Ysg==" rel="nofollow" target="_blank">https://sidoti.zoom.us/webinar/register/WN_4MxVYrk0Sl2JK5ByzTN6Pg</a>. Oragenics will also host virtual one-on-ones with investors on Wednesday and Thursday, May 20-21, 2026. To register for the presentation or one-on-ones, visit <a target="_blank" href="https://www.globenewswire.com/Tracker?data=yC_T3j3QY9A5tFl7LeM-_clsUj9w9Q8jBYRMAOvuDATqlE8o0nxF2hLpcu5HD1vMO8CbWqGYsSp7Kr1eICEEYuWJD_rms9JBOnWdrjPjFiE=" rel="nofollow" target="_blank">www.sidoti.com/events</a>. Registration is free and http://www.streetinsider.com/Globe+Newswire/Oragenics+to+Present+at+Sidoti%E2%80%99s+Micro-Cap+Virtual+Investor+Conference+May+20-21/26518080.html Tue, 19 May 2026 08:45:00 -0400 A.26105522 O.00978679 O.22245537 OGEN http://www.streetinsider.com/Globe+Newswire/Oragenics+to+Present+at+Sidoti%E2%80%99s+Micro-Cap+Virtual+Investor+Conference+May+20-21/26518080.html <p align="justify"><strong>Sarasota, FL, May 19, 2026 (GLOBE NEWSWIRE) -- </strong>Oragenics, Inc. (NYSE American: OGEN) (&quot;Oragenics&quot; or the &quot;Company&quot;), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, will present and host one-on-one meetings with investors at Sidoti’s Micro-Cap Virtual Investor Conference, taking place on May 20-21, 2026.</p> <p align="justify">The presentation will begin at 3:15 ET on May 21, 2026 and can be accessed live here: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=n7TMtW0bYyMXz7G9deH866mpdXRzJw8GqzyNHeMJbfaZDwp-qbxHf38nSwIapDI6gQToDBXo8TD0mKQiesqybKQOgbEjcbfq7do2Gy71oX7MgXe1PnVKfD1H3s7TEBMiNAtmG6XstNQoLeS_g_cbdh_lUxNc6_SdsvXCe1CfGEMaaqWSuND7eTwu5NEcfUGNZ66cvsabvaUbx_hUL49Ysg==" rel="nofollow" target="_blank">https://sidoti.zoom.us/webinar/register/WN_4MxVYrk0Sl2JK5ByzTN6Pg</a>. Oragenics will also host virtual one-on-ones with investors on Wednesday and Thursday, May 20-21, 2026. To register for the presentation or one-on-ones, visit <a target="_blank" href="https://www.globenewswire.com/Tracker?data=yC_T3j3QY9A5tFl7LeM-_clsUj9w9Q8jBYRMAOvuDATqlE8o0nxF2hLpcu5HD1vMO8CbWqGYsSp7Kr1eICEEYuWJD_rms9JBOnWdrjPjFiE=" rel="nofollow" target="_blank">www.sidoti.com/events</a>. Registration is free and http://www.streetinsider.com/Globe+Newswire/Oragenics+to+Present+at+Sidoti%E2%80%99s+Micro-Cap+Virtual+Investor+Conference+May+20-21/26518080.html Tue, 19 May 2026 08:45:00 -0400 A.26105522 O.00978679 O.22245537 OGEN http://www.streetinsider.com/Globe+Newswire/Oragenics+to+Present+at+Sidoti%E2%80%99s+Micro-Cap+Virtual+Investor+Conference+May+20-21/26518080.html <p align="justify"><strong>Sarasota, FL, May 19, 2026 (GLOBE NEWSWIRE) -- </strong>Oragenics, Inc. (NYSE American: OGEN) (&quot;Oragenics&quot; or the &quot;Company&quot;), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, will present and host one-on-one meetings with investors at Sidoti’s Micro-Cap Virtual Investor Conference, taking place on May 20-21, 2026.</p> <p align="justify">The presentation will begin at 3:15 ET on May 21, 2026 and can be accessed live here: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=n7TMtW0bYyMXz7G9deH866mpdXRzJw8GqzyNHeMJbfaZDwp-qbxHf38nSwIapDI6gQToDBXo8TD0mKQiesqybKQOgbEjcbfq7do2Gy71oX7MgXe1PnVKfD1H3s7TEBMiNAtmG6XstNQoLeS_g_cbdh_lUxNc6_SdsvXCe1CfGEMaaqWSuND7eTwu5NEcfUGNZ66cvsabvaUbx_hUL49Ysg==" rel="nofollow" target="_blank">https://sidoti.zoom.us/webinar/register/WN_4MxVYrk0Sl2JK5ByzTN6Pg</a>. Oragenics will also host virtual one-on-ones with investors on Wednesday and Thursday, May 20-21, 2026. To register for the presentation or one-on-ones, visit <a target="_blank" href="https://www.globenewswire.com/Tracker?data=yC_T3j3QY9A5tFl7LeM-_clsUj9w9Q8jBYRMAOvuDATqlE8o0nxF2hLpcu5HD1vMO8CbWqGYsSp7Kr1eICEEYuWJD_rms9JBOnWdrjPjFiE=" rel="nofollow" target="_blank">www.sidoti.com/events</a>. Registration is free and http://www.streetinsider.com/Globe+Newswire/Oragenics+to+Present+at+Sidoti%E2%80%99s+Micro-Cap+Virtual+Investor+Conference+May+20-21/26518080.html Tue, 19 May 2026 08:45:00 -0400 A.26105522 O.00978679 O.22245537 OGEN http://www.streetinsider.com/Globe+Newswire/Oragenics+to+Present+at+Sidoti%E2%80%99s+Micro-Cap+Virtual+Investor+Conference+May+20-21/26518080.html <p align="justify"><strong>Sarasota, FL, May 19, 2026 (GLOBE NEWSWIRE) -- </strong>Oragenics, Inc. (NYSE American: OGEN) (&quot;Oragenics&quot; or the &quot;Company&quot;), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, will present and host one-on-one meetings with investors at Sidoti’s Micro-Cap Virtual Investor Conference, taking place on May 20-21, 2026.</p> <p align="justify">The presentation will begin at 3:15 ET on May 21, 2026 and can be accessed live here: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=n7TMtW0bYyMXz7G9deH866mpdXRzJw8GqzyNHeMJbfaZDwp-qbxHf38nSwIapDI6gQToDBXo8TD0mKQiesqybKQOgbEjcbfq7do2Gy71oX7MgXe1PnVKfD1H3s7TEBMiNAtmG6XstNQoLeS_g_cbdh_lUxNc6_SdsvXCe1CfGEMaaqWSuND7eTwu5NEcfUGNZ66cvsabvaUbx_hUL49Ysg==" rel="nofollow" target="_blank">https://sidoti.zoom.us/webinar/register/WN_4MxVYrk0Sl2JK5ByzTN6Pg</a>. Oragenics will also host virtual one-on-ones with investors on Wednesday and Thursday, May 20-21, 2026. To register for the presentation or one-on-ones, visit <a target="_blank" href="https://www.globenewswire.com/Tracker?data=yC_T3j3QY9A5tFl7LeM-_clsUj9w9Q8jBYRMAOvuDATqlE8o0nxF2hLpcu5HD1vMO8CbWqGYsSp7Kr1eICEEYuWJD_rms9JBOnWdrjPjFiE=" rel="nofollow" target="_blank">www.sidoti.com/events</a>. Registration is free and http://www.streetinsider.com/Globe+Newswire/Oragenics+to+Present+at+Sidoti%E2%80%99s+Micro-Cap+Virtual+Investor+Conference+May+20-21/26518080.html Tue, 19 May 2026 08:45:00 -0400 A.26105522 O.00978679 O.22245537 OGEN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ORAGENICS+INC+++++++++++++For%3A+May+18/26518039.html si-local-file:///var/storage/secattach/20260519/26518039.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ORAGENICS+INC+++++++++++++For%3A+May+18/26518039.html Tue, 19 May 2026 08:38:00 -0400 O.00978679 OGEN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ORAGENICS+INC+++++++++++++For%3A+May+18/26518039.html si-local-file:///var/storage/secattach/20260519/26518039.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ORAGENICS+INC+++++++++++++For%3A+May+18/26518039.html Tue, 19 May 2026 08:38:00 -0400 O.00978679 OGEN http://www.streetinsider.com/Corporate+News/Oragenics+advances+ONP-002+trial+in+Australia%2C+signs+device+licensing+deal/26510790.html <p>Oragenics Inc. (NYSE American: OGEN) reported progress on its Phase IIa clinical trial of ONP-002, an intranasal neurosteroid for concussion treatment, with patient enrollment and dosing underway at sites in Australia.</p><p>The company activated Mackay Base Hospital in March 2026 and began patient enrollment immediately, with the first patient dosed within days of activation. Alfred Hospital in Melbourne was activated in April 2026, with patients being screened for enrollment. Royal Adelaide Hospital completed site initiation and staff training in May 2026, with formal activation pending final approval processes.</p><p>The randomized, placebo-controlled study targets 40 patients and evaluates safety, tolerability, and feasibility of http://www.streetinsider.com/Corporate+News/Oragenics+advances+ONP-002+trial+in+Australia%2C+signs+device+licensing+deal/26510790.html Mon, 18 May 2026 08:31:35 -0400 OGEN http://www.streetinsider.com/FDA/Oragenics+advances+ONP-002+trial+in+Australia%2C+signs+device+licensing+deal/26510790.html <p>Oragenics Inc. (NYSE American: OGEN) reported progress on its Phase IIa clinical trial of ONP-002, an intranasal neurosteroid for concussion treatment, with patient enrollment and dosing underway at sites in Australia.</p><p>The company activated Mackay Base Hospital in March 2026 and began patient enrollment immediately, with the first patient dosed within days of activation. Alfred Hospital in Melbourne was activated in April 2026, with patients being screened for enrollment. Royal Adelaide Hospital completed site initiation and staff training in May 2026, with formal activation pending final approval processes.</p><p>The randomized, placebo-controlled study targets 40 patients and evaluates safety, tolerability, and feasibility of http://www.streetinsider.com/FDA/Oragenics+advances+ONP-002+trial+in+Australia%2C+signs+device+licensing+deal/26510790.html Mon, 18 May 2026 08:31:35 -0400 OGEN http://www.streetinsider.com/Press+Releases/ORAGENICS+PROVIDES+INVESTOR+UPDATE/26510751.html <p><b>A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER</b></p> <p align="justify"><b>Sarasota, FL, May 18, 2026 (GLOBE NEWSWIRE) -- </b>Oragenics, Inc. (NYSE American: OGEN)</p> <p>Dear Fellow Shareholders,</p> <p align="justify">Since our last investor update, Oragenics has continued to execute across all fronts — in the clinic, in the regulatory pipeline, on our balance sheet, and strategically. We have reached a pivotal moment: our Phase IIa clinical trial of ONP-002 is active in Australia, patients are being enrolled and dosed, and we have now signed a Letter of Intent to pursue a licensing agreement for a complementary CNS-related medical device. http://www.streetinsider.com/Press+Releases/ORAGENICS+PROVIDES+INVESTOR+UPDATE/26510751.html Mon, 18 May 2026 08:30:00 -0400 O.00978679 OGEN http://www.streetinsider.com/Press+Releases/ORAGENICS+PROVIDES+INVESTOR+UPDATE/26510751.html <p><b>A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER</b></p> <p align="justify"><b>Sarasota, FL, May 18, 2026 (GLOBE NEWSWIRE) -- </b>Oragenics, Inc. (NYSE American: OGEN)</p> <p>Dear Fellow Shareholders,</p> <p align="justify">Since our last investor update, Oragenics has continued to execute across all fronts — in the clinic, in the regulatory pipeline, on our balance sheet, and strategically. We have reached a pivotal moment: our Phase IIa clinical trial of ONP-002 is active in Australia, patients are being enrolled and dosed, and we have now signed a Letter of Intent to pursue a licensing agreement for a complementary CNS-related medical device. http://www.streetinsider.com/Press+Releases/ORAGENICS+PROVIDES+INVESTOR+UPDATE/26510751.html Mon, 18 May 2026 08:30:00 -0400 O.00978679 OGEN http://www.streetinsider.com/Globe+Newswire/ORAGENICS+PROVIDES+INVESTOR+UPDATE/26510751.html <p><b>A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER</b></p> <p align="justify"><b>Sarasota, FL, May 18, 2026 (GLOBE NEWSWIRE) -- </b>Oragenics, Inc. (NYSE American: OGEN)</p> <p>Dear Fellow Shareholders,</p> <p align="justify">Since our last investor update, Oragenics has continued to execute across all fronts — in the clinic, in the regulatory pipeline, on our balance sheet, and strategically. We have reached a pivotal moment: our Phase IIa clinical trial of ONP-002 is active in Australia, patients are being enrolled and dosed, and we have now signed a Letter of Intent to pursue a licensing agreement for a complementary CNS-related medical device. http://www.streetinsider.com/Globe+Newswire/ORAGENICS+PROVIDES+INVESTOR+UPDATE/26510751.html Mon, 18 May 2026 08:30:00 -0400 O.00978679 OGEN http://www.streetinsider.com/Globe+Newswire/ORAGENICS+PROVIDES+INVESTOR+UPDATE/26510751.html <p><b>A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER</b></p> <p align="justify"><b>Sarasota, FL, May 18, 2026 (GLOBE NEWSWIRE) -- </b>Oragenics, Inc. (NYSE American: OGEN)</p> <p>Dear Fellow Shareholders,</p> <p align="justify">Since our last investor update, Oragenics has continued to execute across all fronts — in the clinic, in the regulatory pipeline, on our balance sheet, and strategically. We have reached a pivotal moment: our Phase IIa clinical trial of ONP-002 is active in Australia, patients are being enrolled and dosed, and we have now signed a Letter of Intent to pursue a licensing agreement for a complementary CNS-related medical device. http://www.streetinsider.com/Globe+Newswire/ORAGENICS+PROVIDES+INVESTOR+UPDATE/26510751.html Mon, 18 May 2026 08:30:00 -0400 O.00978679 OGEN http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++ORAGENICS+INC+++++++++++++For%3A+May+08/26460983.html si-local-file:///var/storage/secattach/20260508/26460983.html http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++ORAGENICS+INC+++++++++++++For%3A+May+08/26460983.html Fri, 08 May 2026 16:06:00 -0400 O.00978679 OGEN http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++ORAGENICS+INC+++++++++++++For%3A+May+08/26460983.html si-local-file:///var/storage/secattach/20260508/26460983.html http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++ORAGENICS+INC+++++++++++++For%3A+May+08/26460983.html Fri, 08 May 2026 16:06:00 -0400 O.00978679 OGEN http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++ORAGENICS+INC+++++++++++++For%3A+Mar+31/26460843.html si-local-file:///var/storage/secattach/20260508/26460843.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++ORAGENICS+INC+++++++++++++For%3A+Mar+31/26460843.html Fri, 08 May 2026 16:02:00 -0400 O.00978679 OGEN http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++ORAGENICS+INC+++++++++++++For%3A+Mar+31/26460843.html si-local-file:///var/storage/secattach/20260508/26460843.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++ORAGENICS+INC+++++++++++++For%3A+Mar+31/26460843.html Fri, 08 May 2026 16:02:00 -0400 O.00978679 OGEN http://www.streetinsider.com/Corporate+News/Oragenics+signs+letter+of+intent+to+license+blood+purification+technology/26449181.html <p>Oragenics Inc. (NYSE American: OGEN) signed a letter of intent to license CardioDialysis technology from Sigyn Therapeutics Inc. (OTCQB: SIGY) for treating traumatic brain injury and other chronic neurodegenerative diseases, according to a company statement.</p><p>The proposed exclusive license would allow Oragenics to develop and commercialize the blood purification technology, which removes inflammatory and pathogenic molecules from the bloodstream. The company plans to combine this approach with its existing ONP-002 neurosteroid treatment, currently in Phase IIa clinical trials for concussion and mild traumatic brain injury.</p><p>Under the proposed terms, Oragenics would issue 3.25 million shares of restricted preferred stock to Sigyn, convertible http://www.streetinsider.com/Corporate+News/Oragenics+signs+letter+of+intent+to+license+blood+purification+technology/26449181.html Thu, 07 May 2026 08:30:37 -0400 OGEN SIGY SIGYD